Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Merit Medical Systems ( (MMSI) ) has shared an update.
Merit Medical Systems has released historical revenue data reclassified into new foundational and therapeutic product categories for the fiscal years 2022 through 2025, showing total revenue rising from about $1.15 billion in 2022 to $1.52 billion in 2025. Foundational products contributed the larger share, increasing from $862.4 million to $1.03 billion over the period, while therapeutic products grew faster, from $288.6 million to $487.4 million, underscoring the expansion of higher-growth therapy lines.
Quarterly figures for 2025 versus 2024 show consistent year-over-year gains in both categories, with total quarterly revenue rising in each comparable period, highlighting sustained demand across Merit’s portfolio. The company also provided a one-time breakout of revenue by detailed product platforms such as Access, Vascular Intervention, Oncology, Cardiac Therapies, and Renal Therapies, indicating broad-based growth across core and specialty segments and giving investors enhanced transparency into the evolving composition of Merit’s revenue, though it does not plan to update this platform-level view regularly.
The most recent analyst rating on (MMSI) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Merit Medical Systems stock, see the MMSI Stock Forecast page.
Spark’s Take on MMSI Stock
According to Spark, TipRanks’ AI Analyst, MMSI is a Neutral.
The score is driven primarily by strong financial performance (improving profitability and robust cash flow). This is offset by weak technical signals (price below key moving averages and negative momentum) and a relatively expensive valuation (high P/E). Earnings call commentary is constructive on full-year growth and cash flow but tempered by tariffs, OEM destocking, divestiture headwinds, and softer near-term margin guidance.
To see Spark’s full report on MMSI stock, click here.
More about Merit Medical Systems
Merit Medical Systems, Inc. is a medical device company that develops and manufactures a broad range of foundational and therapeutic products used in interventional, diagnostic, and therapeutic procedures. Its portfolio spans access tools, vascular intervention devices, OEM offerings, and specialized platforms in oncology, cardiac, renal, and endoscopy markets, reflecting a diversified presence across key healthcare segments.
The company serves global hospital and clinic customers with solutions that support minimally invasive treatments and procedural efficiency. By organizing its portfolio into foundational and therapeutic categories, Merit aims to clarify its revenue drivers across core device platforms and higher-growth specialty therapies, offering investors and stakeholders greater visibility into business mix and performance trends.
Average Trading Volume: 753,485
Technical Sentiment Signal: Sell
Current Market Cap: $4.06B
Find detailed analytics on MMSI stock on TipRanks’ Stock Analysis page.